Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

One-Year Follow-Up of Vascular Intervention Trials Disrupted by the COVID-19 Pandemic: A Use-Case landscape.

Cardiovascular revascularization medicine : including molecular interventions·2022

Same author

Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2022

Same author

Subclinical Leaflet Thrombosis and Anticoagulation After Transcatheter Aortic Valve Replacement: A Review.

JAMA cardiology·2022

Same author

Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Final 2-Year Results From Onyx ONE.

JACC. Cardiovascular interventions·2022

Same author

Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.

JAMA cardiology·2022

Same author

Treatment Gaps in Guideline-Directed Medical Therapy for Patients Undergoing Higher-Risk Percutaneous Coronary Intervention.

Circulation. Cardiovascular interventions·2022

Same journal

Successful Management of a Distal Left Main Perforation Using the Jailed-balloon Technique and Covered Stent Fenestration.

Interventional cardiology (London, England)·2026

Same journal

Complete Revascularisation in ST-elevation MI: Do We Really Buy It? Challenging the Current Approach to Bystander Percutaneous Coronary Intervention.

Interventional cardiology (London, England)·2026

Same journal

Acute Performance of the DynamX Bioadaptor in Complex Coronary Lesions: An Optical Coherence Tomography-based Evaluation.

Interventional cardiology (London, England)·2026

Same journal

Optimal Fluoroscopic Angles for Percutaneous Coronary Intervention During Mechanical Cardiopulmonary Resuscitation in Cardiac Arrest Patients.

Interventional cardiology (London, England)·2026

Same journal

Safety and Effectiveness of Hypothermia as Adjunctive Therapy in Percutaneous Coronary Intervention for ST-elevation MI: A Comprehensive Meta-analysis.

Interventional cardiology (London, England)·2026

Same journal

Ultimaster TANSEI Stent in Complex Coronary Lesions: The EPIC08 TANSEI COMPLEX Study.

Interventional cardiology (London, England)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 17, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Revascularisation for Ischaemic Cardiomyopathy.

Matthew E Li Kam Wa¹, Saba Z Assar², Ajay J Kirtane^2,3

¹Coronary Research Group, British Heart Foundation Centre of Research Excellence, King's College London London, UK.

Interventional Cardiology (London, England)

|September 1, 2023

Summary

This summary is machine-generated.

Percutaneous coronary intervention may offer benefits similar to bypass surgery for heart failure patients with coronary artery disease, but without the surgical risks. The REVIVED-BCIS2 trial provides new insights into this approach.

Keywords:

Heart failure REVIVED STICH ischaemic cardiomyopathy percutaneous coronary intervention reduced ejection fraction stable coronary artery disease

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

Model of Ischemia and Reperfusion Injury in Rabbits

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

Related Experiment Videos

Last Updated: Jul 17, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Author Spotlight: Enhancing Coronary Artery Revascularization

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

Model of Ischemia and Reperfusion Injury in Rabbits

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

Area of Science:

Cardiology
Interventional Cardiology
Heart Failure Research

Background:

Coronary artery disease (CAD) is a primary cause of heart failure with reduced ejection fraction (HFrEF).
Coronary artery bypass grafting (CABG) improves quality of life and long-term outcomes but carries significant short-term risks in patients with severely impaired left ventricular (LV) function.
The optimal revascularization strategy for patients with ischemic cardiomyopathy remains a clinical challenge.

Purpose of the Study:

To evaluate the efficacy and safety of percutaneous coronary intervention (PCI) compared to optimal medical therapy (OMT) in patients with ischemic LV dysfunction.
To assess whether PCI can provide similar benefits to CABG without the associated surgical hazards.
To inform clinical decision-making regarding revascularization in patients with stable CAD and HFrEF.

Main Methods:

The REVIVED-BCIS2 trial (NCT01920048) was a randomized controlled trial.
It compared outcomes of PCI plus OMT versus OMT alone in patients with ischemic cardiomyopathy and viable LV myocardium.
Key endpoints included mortality, hospitalizations for heart failure, and quality of life measures.

Main Results:

The trial results are examined in detail within this review.
Preliminary findings suggest PCI may have a role in selected patients, but further analysis is ongoing.
The review discusses the implications of the trial for clinical practice and future research directions.

Conclusions:

The REVIVED-BCIS2 trial provides crucial data on the role of PCI in ischemic cardiomyopathy.
This review proposes a potential pathway for patient selection and revascularization decisions.
Unanswered questions regarding the long-term benefits and optimal patient profiles for PCI are explored.